AC Immune SA
↗Lausanne, Switzerland
AC Immune is a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases. The company focuses on the discovery, design, and development of therapeutic and diagnostic products for conditions such as Alzheimer's disease, Parkinson's disease, and various NeuroOrphan indications driven by misfolded proteins.
Leveraging its proprietary technology platforms, SupraAntigen® and Morphomer®, AC Immune develops a diverse pipeline of active immunotherapies, antibodies, small molecules, and diagnostic PET tracers. The company maintains a strong track record of strategic partnerships with major global pharmaceutical firms to advance its research and clinical programs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$1M-$10M
Founded:2003
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$120M
Investors:BVF Partners
STOCK
Exchange:NASDAQ
Ticker:ACIU
Market Cap:$0.32B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule, mAb, Active immunotherapy, PET tracers
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Janssen Pharmaceuticals, Takeda, Eli Lilly, Genentech/Roche
COMPETITION
Position:Emerging
Competitors:Alector, BeiGene, BioNTech
LEADERSHIP
Key Executives:
Andrea Pfeifer - CEO
Johannes Streffer - Chief Medical Officer
Scientific Founders:Andrea Pfeifer
LINKS
Website:acimmune.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of AC Immune SA and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AC Immune SA. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.